How Long Does Ajovy (Fremanezumab) Take to Work?

How Long Does Fremanezumab Actually Take to Work?

If you just started Ajovy and are wondering when something will change, here is the honest answer: most people notice a measurable difference in their migraines within the first month, and some early responders feel a shift in the first week or two. That said, the full benefit builds gradually, and three to six months is the window where most patients see their best results. Knowing this upfront makes it much easier to stay the course.

The HALO trials (the large clinical studies that led to fremanezumab's approval) showed statistically significant reductions in monthly migraine days by the end of week four for both dosing schedules. Roughly 40% of participants achieved a 50% or greater reduction in migraine days within that first month alone. Those are real numbers worth holding onto when you are in the middle of an uncertain wait.

What Do the First 30 Days Look Like?

The first month with fremanezumab is less about dramatic change and more about watching for early signals. A meaningful number of patients do report shorter or less intense migraines in the first one to two weeks, though this is not universal and individual responses vary widely.

Here is what tends to happen during this period:

• Migraine frequency: May begin to decrease, though some weeks will still feel like your baseline.
• Migraine severity: Some patients notice attacks are easier to treat with their usual rescue medications.
• Injection-site reactions: The most common side effect in the first month is mild redness or discomfort at the injection site. This is not a sign the medication is or is not working.
• Expectation effects: Early perceived improvement can reflect a genuine drug response or a placebo-type effect. Keeping a headache diary helps you tell the difference over time.

If you feel nothing has changed by week four, that is discouraging but not a verdict. Many patients who become solid responders at month three had a quiet first month.

Monthly vs. Quarterly Dosing: Does the Schedule Change How Fast It Works?

This is a common question, and the short answer is: not meaningfully. Fremanezumab comes in a 225 mg monthly injection or a 675 mg quarterly injection. The quarterly dose delivers more medication upfront, which sounds like it would work faster, but head-to-head trial comparisons did not show a reliable advantage in early onset for most patients.

The choice between schedules is usually about convenience and adherence, not speed. If you prefer fewer injections and can tolerate the idea of a larger dose every three months, quarterly may suit you. If you want more flexibility to adjust your plan with your doctor in smaller increments, monthly may be a better fit.

When Should You Decide Fremanezumab Is Not Working?

Most neurologists recommend a minimum of 12 weeks (three months) before concluding that a CGRP-pathway (calcitonin gene-related peptide) inhibitor has failed. Late responders are well-documented with this class of drugs, and stopping at six or eight weeks risks missing a response that was still building.

That said, some signals warrant earlier reassessment:

• Zero change in migraine frequency or severity at eight weeks with no complicating factors
• New or worsening cardiovascular symptoms after starting the medication
• Significant new side effects that are affecting your quality of life

If any of these apply, reach out to your prescribing clinician rather than waiting out the full three months.

Factors That Can Affect Your Timeline

Not everyone responds on the same schedule, and a few specific factors may influence how quickly you notice results.

Medication-overuse headache (a cycle where taking acute pain relievers too frequently causes more headaches) deserves special attention. It is one of the most common hidden factors that makes fremanezumab appear less effective than it actually is. If you are taking triptans, opioids, or over-the-counter pain relievers more than ten days per month, talking to your doctor about tapering before or alongside starting Ajovy is genuinely worth the conversation.

What Is Overstated About Fremanezumab?

It is worth naming a few things that get oversold, because unrealistic expectations are one of the main reasons people stop a medication that might have worked.

"Rapid relief" language in marketing materials can set an unfair benchmark. Most patients need two to three months for robust, consistent benefit. A partial response in month one is a positive signal, not a disappointment.

Week-one complete elimination of migraines shows up in patient testimonials and social media posts fairly often. These are real experiences, but they represent the far end of the response curve. Treating them as the expected outcome will make most people's actual experience feel like a failure when it is not.

Fremanezumab as an acute rescue treatment is another misconception worth clearing up. Even though it works on the CGRP pathway, it is a preventive medication only. It has no proven benefit for stopping an active migraine attack. You will still need a separate rescue plan for migraines that break through while the preventive takes hold.

Patience with this medication is not passive waiting. It is part of the treatment.

Frequently Asked Questions

Can fremanezumab start working in the first week?

Some early responders do report fewer or shorter migraines within the first one to two weeks. This is real but not typical. Most patients need at least four weeks before noticing a reliable reduction in migraine frequency or severity.

What happens if Ajovy doesn't work after 3 months?

Your neurologist may reassess your diagnosis, review medication-overuse patterns, or consider a different CGRP-pathway treatment. Other preventive options exist, and a partial response at three months may still improve with continued use.

Is the quarterly fremanezumab dose better than monthly for faster results?

Clinical trial data suggests both schedules have similar onset timing. The quarterly dose delivers a higher initial concentration, but this does not reliably produce faster relief. Schedule choice typically comes down to personal preference and adherence.

How do I know if fremanezumab is working or if my migraines just improved on their own?

Tracking migraine days in a headache diary before and after starting treatment is the most reliable way to measure real change. A 50% or greater reduction in monthly migraine days is the benchmark used in clinical trials.

Can I take my usual migraine medications while waiting for fremanezumab to kick in?

Yes, your doctor will likely keep your acute rescue medications in place during the trial period. However, overusing triptans or pain relievers more than ten days per month can mask fremanezumab's effectiveness and worsen headache patterns.

The Bottom Line

Fremanezumab works on a slower timeline than many patients expect, and that is completely normal. Early partial relief in the first month is a positive signal worth building on, not a reason to give up. The clinical standard is a three-month minimum trial, because late responders are well-documented with this class of medication. Tracking your migraine days honestly, addressing any medication overuse, and staying in regular contact with your care team all improve your chances of a meaningful outcome. Doctronic offers free AI consultations and $39 video visits, available 24/7, to help you track your response and decide when to reassess with a licensed clinician. This article is informational and is not a medical diagnosis. Confirm with a licensed clinician, especially for new, worsening, or high-risk symptoms.